Edwin Coe advises Onzima Ventures Plc on Reverse Takeover and Re-admission to AIM
Edwin Coe advised Onzima Ventures Plc on the acquisition of the remaining 51% of the issued shares of N4 Pharma Limited which it did not already own. The transaction constituted a Reverse Takeover and entailed the re-admission of the enlarged entity to AIM.
The company also raised £1.5 million via a share placing which, it said, will be used to fund the development of additional patent applications for reformulations of a wide range of generic drugs, to undertake clinical trials for N4 Pharma’s reformulation of sildenafil and for working capital purposes.
The Edwin Coe team was led by Head of Corporate & Commercial Russel Shear, who commented: “We are delighted to have assisted Onzima Ventures on this acquisition and its re-admission to AIM as N4 Pharma.”
About Edwin Coe
Discreet strength. Clear judgement. Enduring relationships.
Founded in 1913 and based in Lincoln's Inn, Edwin Coe is a leading independent London law firm built on clarity, collaboration and trust. We specialise in dispute resolution, private capital and cross-border matters.
What began as a boutique disputes practice over 100 years ago has evolved into a firm advising private clients, entrepreneurs, family offices, UK and international businesses across the areas of corporate, private client, real estate and litigation. Throughout that evolution, one thing has remained constant – our belief that the best advice combines legal insight with human understanding.
Collaborative in approach. Committed in purpose. Connected where it matters most.
